BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Rhucin regulatory update

Pharming submitted a BLA to FDA for Rhucin to treat acute angioedema attacks in patients with hereditary angioedema (HAE). Santarus Inc. (NASDAQ:SNTS, San...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >